The future for blood-stage vaccines against malaria

Immunology and Cell Biology

Volumn 87, Issue 5, 2009, Pages 377-390

  Richards, Jack S ^a   Beeson, James G ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b Walter and Eliza Hall Institute OfMedical Research ^*  (Australia)

Author keywords

Blood stage; Malaria; Merozoite; Plasmodium; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIMALARIAL AGENT; APICAL MEMBRANE ANTIGEN 1; DNA VACCINE; ERYTHROCYTE BINDING ANTIGEN 175 R2; GLUTAMATE RICH PROTEIN; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEMBRANE ANTIGEN; MEROZOITE SURFACE PROTEIN 1 19; MEROZOITE SURFACE PROTEIN 1 42; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3; MONTANIDE ISO 720; NYVAC PF7 VACCINE; PEPTIDE VACCINE; RECOMBINANT ANTIGEN; SERINE REPEAT ANTIGEN 5; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIBODY TITER; ANTIGEN PRESENTATION; B LYMPHOCYTE; BLOOD PARASITE; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE TRANSMISSION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALARIA; MEROZOITE; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, PROTOZOAN; CLINICAL TRIALS AS TOPIC; ERYTHROCYTES; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM FALCIPARUM;

ANIMALIA;

EID: 68149089667     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.27     Document Type: Review

References (244)

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434: 214-217.
2. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008; 5:e38.
3. Hay SI, Snow RW. The Malaria Atlas Project: developing global maps of malaria risk. PLoS Med 2006; 3:e473.
4. World Health Organization. World Health Report: Make Every Mother and Child Count. WHO: Geneva, 2005; cited 15/3/06. Available from: http://www.who.int/whr/2005/en/ index.html.
5. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419: 498-511.
6. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 2008; 455: 757-763.
7. Carlton JM, Angiuoli SV, Suh BB, Kooij TW, Pertea M, Silva JC et al. Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 2002; 419: 512-519.
8. Pain A, Bohme U, Berry AE, Mungall K, Finn RD, Jackson AP et al. The genome of the simian and human malaria parasite Plasmodium knowlesi. Nature 2008; 455: 799-803.
9. Holt RA, Subramanian GM, Halpern A, Sutton GG, Charlab R, Nusskern DR et al. The genome sequence of the malaria mosquito Anopheles gambiae. Science 2002; 298: 129-149.
10. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
11. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
12. Noor AM, Mutheu JJ, Tatem AJ, Hay SI, Snow RW. Insecticide-treated net coverage in Africa: mapping progress in 2000-2007. Lancet 2009; 373:58-67.
13. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS et al. Atrialof combination antimalarial therapies in children from Papua New Guinea. NEngl J Med 2008; 359: 2545-2557.
14. Malaria's watershed. Nature 2008; 455:707.
15. Hall N, Karras M, Raine JD, Carlton JM, Kooij TW, Berriman M et al. A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science 2005; 307:82-86.
16. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005; 366: 2012-2018.
17. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364: 1411-1420.
18. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J et al. Efficacy of RTS,S/ AS01E vaccine against malaria in children 5-17 months of age. NEngl J Med 2008; 359: 2521-2532.
19. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. NEngl J Med 2008; 359: 2533-2544.
20. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358: 1927-1934.
21. Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 2005; 23: 4148-4157.
22. Elliott SR, Beeson JG. Estimating the burden of global mortality in children aged <5 years by pathogen-specific causes. Clin Infect Dis 2008; 46: 1794-1795.
23. Gilson PR, Crabb BS. Morphology and kinetics of the three distinct phases of red blood cell invasion byPlasmodium falciparum merozoites. Int JParasitol 2009; 39: 91-96.
24. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature 2002; 415: 673-679.
25. Beeson JG, Brown GV. Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation. Cell Mol Life Sci 2002; 59: 258-271.
26. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006; 28:51-60.
27. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M et al. Theriskof malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg 2007; 76: 997-1008.
28. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev 2009; 22:13-36.
29. Beeson JG, Osier FH, Engwerda CR. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol 2008; 24:578-584.
30. Douradinha B, Mota MM, Luty AJ, Sauerwein RW. Cross-species immunity in malaria vaccine development: two, three, or even four for the price of one? Infect Immun 2008; 76: 873-878.
31. Cohen S, McGregorI, Carrington S. Gamma-globulin and acquiredimmunitytohuman malaria. Nature 1961; 192: 733-737.
32. McGregor IA. The passive transfer of human malarial immunity. Am JTropMedHyg 1964; 13 (Suppl): 237-239.
33. Tongren JE, Drakeley CJ, McDonald SL, Reyburn HG, Manjurano A, Nkya WM et al. Target antigen, age, and duration of antigen exposure independently regulate immu- noglobulin G subclass switching in malaria. Infect Immun 2006; 74:257-264.
34. Taylor RR, Smith DB, Robinson VJ, McBrideJS, RileyEM. Human antibodyresponse to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun 1995; 63: 4382-4388.
35. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 2008; 76: 759-766.
36. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S et al. IgG subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control ofparasitemiaandprotection from symptomaticillness. Infect Immun 2009; 77: 1165-1174.
37. Bergmann-Leitner ES, Duncan EH, Mullen GE, Burge JR, Khan F, Long CA et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg 2006; 75: 437-442.
38. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. JExpMed1990; 172: 1633-1641.
39. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. JExpMed1995; 182:409-418.
40. Diggs CL, Osler AG. Humoral immunity in rodent malaria. III: studies on the site of antibodyaction. JImmunol 1975; 114: 1243-1247.
41. Mitchell GH, Butcher GA, Voller A, Cohen S. Theeffectofhuman immuneIgG on the in vitro development of Plasmodium falciparum. Parasitology1976; 72: 149-162.
42. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A et al. Arecombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selectivepressureon parasitepopulations in a phase1-2b trial in Papua NewGuinea. JInfectDis2002; 185: 820-827.
43. Ling IT, Ogun SA, Holder AA. Immunization against malaria with a recombinant protein. Parasite Immunol 1994; 16:63-67.
44. Perera KL, Handunnetti SM, Holm I, Longacre S, Mendis K. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect Immun 1998; 66: 1500-1506.
45. Crewther PE, Matthew ML, Flegg RH, Anders RF. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain- specific epitopes. Infect Immun 1996; 64: 3310-3317.
46. Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, Sulzer AJ et al. Protectiveimmunityinduced in squirrel monkeys with recombinantapical membrane antigen-1 of Plasmodium fragile. Am JTropMedHyg1994; 51: 711-719.
47. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP againstmalaria infection in Gambian adults. PLoSMed2004; 1:e33.
48. Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S et al. Aphase2b randomisedtrial ofthecandidatemalariavaccinesFP9 ME-TRAP and MVAME-TRAP among children in Kenya. PLoS Clin Trials 2006; 1:e29.
49. Feachem R, Sabot O. A new global malaria eradication strategy. Lancet 2008; 371: 1633-1635.
50. World Health Organization. TheRoleBackMalariaPartnership. GlobalMalariaAction Plan. WHO: Geneva, 2008.
51. Volkman SK, Hartl DL, Wirth DF, Nielsen KM, Choi M, Batalov S et al. Excess polymorphisms in genes for membrane proteins in Plasmodium falciparum. Science 2002; 298: 216-218.
52. Polley SD, Conway DJ. Strong diversifying selection on domains of the Plasmodium falciparum apical membraneantigen 1 gene. Genetics2001; 158: 1505-1512.
53. Miller LH, Roberts T, Shahabuddin M, McCutchan TF. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol 1993; 59:1-14.
54. Smythe JA, Peterson MG, Coppel RL, Saul AJ, Kemp DJ, Anders RF. Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum. Mol Biochem Parasitol 1990; 39:227-234.
55. CortesA. SwitchingPlasmodiumfalciparumgeneson andofffor erythrocyteinvasion. Trends Parasitol 2008; 24: 517-524.
56. Persson KE, McCallum FJ, ReilingL, Lister NA, Stubbs J, Cowman AF et al. Variation in use of erythrocyte invasion pathways byPlasmodium falciparum mediates evasion of human inhibitoryantibodies. JClinInvest2008; 118:342-351.
57. Baum J, Maier AG, Good RT, Simpson KM, Cowman AF. Invasion by P. falciparum merozoitessuggestsahierarchyofmolecularinteractions. PLoSPathog2005; 1:e37.
58. Guevara Patino JA, Holder AA, McBride JS, Blackman MJ. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked bynaturallyacquired human antibodies. JExpMed1997; 186: 1689-1699.
59. Miura K, Zhou H, MoretzSE, Diouf A, Thera MA, Dolo A et al. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. JImmunol2008; 181: 8776-8783.
60. StanisicDI, Martin LB, Gatton ML, GoodMF. Inhibition of19-kDaC-terminal region of merozoite surface protein-1-specific antibody responses in neonatal pups by maternally derived 19-kDa C-terminal region of merozoite surface protein-1-specific antibodies but not whole parasite-specific antibodies. J Immunol 2004; 172: 5570-5581.
61. Wykes MN, Good MF. What really happens to dendritic cells during malaria? Nature Rev 2008; 6: 864-870.
62. Wykes MN, Liu XQ, Beattie L, Stanisic DI, Stacey KJ, Smyth MJ et al. Plasmodium strain determines dendritic cell function essential for survival from malaria. PLoS Pathog2007; 3:e96.
63. Xiao L, Rafi-Janajreh A, Patterson P, Zhou Z, Lal AA. Adjuvants and malaria vaccine development. Chem Immunol 2002; 80: 343-365.
64. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. JInfectDis2002; 185: 1155-1164.
65. Collins WE, Jeffery GM. A retrospective examination of secondary sporozoite- and trophozoite- induced infections with Plasmodium falciparum: development of para- sitologic and clinical immunity following secondary infection. Am J Trop Med Hyg 1999; 61 :20-35.
66. Brown KN, Brown IN. Immunitytomalaria: antigenicvariation in chronicinfectionsof Plasmodium knowlesi. Nature 1965; 208: 1286-1288.
67. Jones TR, Obaldia III N, Gramzinski RA, Hoffman SL. Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. Am J Trop Med Hyg 2000; 62: 675-680.
68. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N et al. Immunityto malaria after administration of ultra-lowdoses of red cells infected with Plasmodium falciparum. Lancet 2002; 360: 610-617.
69. Renia L, Gruner AC, Mauduit M, Snounou G. Vaccination against malaria with live parasites. Expert Rev Vaccines2006; 5: 473-481.
70. Wykes M, Good MF. A case for whole-parasite malaria vaccines. Int JParasitol 2007; 37: 705-712.
71. Pinzon-CharryA, Good MF. Malaria vaccines: thecasefor a whole-organism approach. Expert Opin Biol Ther2008; 8: 441-448.
72. Patarroyo ME, Patarroyo MA. Emerging rules for subunit-based, multiantigenic, multistage chemicallysynthesized vaccines. Acc ChemRes2008; 41:377-386.
73. Corradin G, Spertini F, Verdini A. Medicinal application of long synthetic peptide technology. Expert Opin BiolTher2004; 4: 1629-1639.
74. Satterthwait AC, Chiang LC, Arrhenius T, Cabezas E, Zavala F, Dyson HJ et al. The conformational restriction of synthetic vaccines for malaria. Bull WorldHealth Organ 1990; 68:17-25.
75. Jackson DC, Purcell AW, Fitzmaurice CJ, Zeng W, Hart DN. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Curr Drug Targets 2002; 3: 175-196.
76. Riley EM, Olerup O, Bennett S, Rowe P, Allen SJ, Blackman MJ et al. MHC and malaria: the relationship between HLA class II alleles and immune responses to Plasmodium falciparum. Int Immunol 1992; 4: 1055-1063.
77. Doolan DL, Hoffman SL. DNA-based vaccines against malaria: status and promise of the multi-stage malaria DNA vaccine operation. Int JParasitol 2001; 31: 753-762.
78. Dunachie SJ, Hill AV. Prime-boost strategies for malaria vaccine development. JExp Biol 2003; 206: 3771-3779.
79. Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 2004; 199: 126-143.
80. Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ et al. Viral vectors for malaria vaccine development. Vaccine 2007; 25: 2567-2574.
81. Reyes-Sandoval A, Harty JT, Todryk SM. Viral vector vaccines make memory T cells against malaria. Immunology2007; 121: 158-165.
82. Tyagi RK, Sharma PK, Vyas SP, Mehta A. Various carrier system(s)-mediated genetic vaccination strategies against malaria. Expert Rev Vaccines 2008; 7: 499-520.
83. Sanders PR, Cantin GT, Greenbaum DC, Gilson PR, Nebl T, Moritz RL et al. Identification of protein complexes in detergent-resistant membranes of Plasmodium falciparum schizonts. Mol Biochem Parasitol 2007; 154: 148-157.
84. Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, Carucci DJ et al. Distinct protein classesincludingnovel merozoitesurfaceantigensin Raft-likemembranes of Plasmodium falciparum. JBiolChem2005; 280: 40169-40176.
85. Mu J, Awadalla P, Duan J, McGee KM, Keebler J, Seydel K et al. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nature genet 2007; 39: 126-130.
86. Doolan DL, Aguiar JC, Weiss WR, Sette A, Felgner PL, Regis DP et al. Utilization of genomic sequence information to develop malaria vaccines. JExpBiol 2003; 206: 3789-3802.
87. Winzeler EA. Applied systems biologyand malaria. Nature Rev2006; 4: 145-151.
88. Winzeler EA. Malariaresearch in thepost-genomicera. Nature2008; 455: 751-756.
89. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 2002; 419: 520-526.
90. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell 2006; 124: 755-766.
91. Gerold P, Schofield L, Blackman MJ, Holder AA, Schwarz RT. Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and -2 of Plasmodium falciparum. Mol Biochem Parasitol 1996; 75: 131-143.
92. Holder AA, Freeman RR. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 1981; 294: 361-364.
93. Blackman MJ, Ling IT, Nicholls SC, Holder AA. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragmentcontainingtwoepidermal growth factor-likedomains. MolBiochemParasitol 1991; 49:29-33.
94. Chitarra V, Holm I, Bentley GA, Petres S, Longacre S. The crystal structure of C-terminal merozoitesurfaceprotein 1 at1.8 Aresolution, ahighlyprotectivemalaria vaccine candidate. Mol Cell 1999; 3:457-464.
95. Pizarro JC, Chitarra V, Verger D, Holm I, Petres S, Dartevelle S et al. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. JMol Biol 2003; 328: 1091-1103.
96. Goel VK, Li X, Chen H, Liu SC, Chishti AH, Oh SS. Band 3 is a host receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion of erythro- cytes. Proc Natl AcadSci USA 2003; 100: 5164-5169.
97. Li X, ChenH, OoTH, DalyTM, Bergman LW, Liu SCet al. Aco-ligandcomplexanchors Plasmodium falciparummerozoites to the erythrocyte invasion receptor band 3. JBiol Chem 2004; 279: 5765-5771.
98. Polley SD, Tetteh KK, Cavanagh DR, Pearce RJ, Lloyd JM, Bojang KA et al. Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria. Infect Immun 2003; 71: 1833-1842.
99. RileyEM, Allen SJ, Wheeler JG, Blackman MJ, BennettS, Takacs B et al. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 1992; 14:321-337.
100. Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL et al. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surfaceprotein-1 19-kiloDalton domain of Plasmodiumfalciparumin pregnantwomen and infants: associations with febrileillness, parasitemia, and anemia. AmJTropMed Hyg1998; 58: 211-219.
101. Egan AF, BurghausP, DruilheP, HolderAA, RileyEM. Human antibodiestothe19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 1999; 21: 133-139.
102. Dodoo D, Theander TG, Kurtzhals JA, Koram K, RileyE, Akanmori BD et al. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun 1999; 67: 2131-2137.
103. O'Donnell RA, deKoning-Ward TF, BurtRA, BockarieM, Reeder JC, Cowman AF et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. JExpMed2001; 193: 1403-1412.
104. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA. Antibodies inhibit the protease- mediated processing of a malaria merozoite surface protein. JExpMed1994; 180: 389-393.
105. Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum42-kilodalton C-terminal merozoitesurfaceprotein 1. InfectImmun2003; 71: 6766-6774.
106. Daly TM, Long CA. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infect Immun 1993; 61: 2462-2467.
107. Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med 1995; 1: 325-332.
108. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 2006; 24: 3009-3017.
109. Stoute JA, GombeJ, Withers MR, Siangla J, McKinneyD, Onyango M et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007; 25: 176-184.
110. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A et al. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials2006; 1:e34.
111. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in western Kenya. PLoS ONE 2009; 4:e4708.
112. Malkin E, LongCA, StowersAW, Zou L, Singh S, Macdonald NJet al. Phase1 studyof two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin Trials 2007; 2:e12.
113. Pan W, Huang D, ZhangQ, Qu L, Zhang D, Zhang X et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. JImmunol2004; 172: 6167-6174.
114. Langermans JA, Hensmann M, van Gijlswijk M, Zhang D, Pan W, Giersing BK et al. Preclinical evaluation of a chimeric malaria vaccine candidate in montanide ISA 720((R)): immunogenicity and safety in Rhesus macaques. Human Vaccin 2006; 2: 222-226.
115. Hu J, Chen Z, Gu J, Wan M, Shen Q, KienyMP et al. Safetyand immunogenicityof a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthyadults. PLoS ONE 2008; 3: e1952.
116. MalkinE,Hu J, LiZ, Chen Z, BiX, ReedZ et al. A Phase 1 trial of PfCP2.9: An AMA1/ MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008; 26: 6864-6873.
117. Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, Mendez F et al. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am JTropMedHyg2005; 73:16-24.
118. PolleySD, ConwayDJ, Cavanagh DR, McBride JS, LoweBS, Williams TN et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 2006; 24: 4233-4246.
119. Sturchler D, Berger R, Rudin C, Just M, Saul A, Rzepczyk C et al. Safety, immuno- genicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood- stagecombination vaccinein Swiss adults. AmJTropMedHyg1995; 53: 423-431.
120. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine1999; 17: 3145-3159.
121. Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, Cloonan N et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000; 18: 1925-1931.
122. GentonB,Al-YamanF,AndersR,SaulA,BrownG,PyeDet al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea [In Process Citation]. Vaccine 2000; 18: 2504-2511.
123. Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003; 22:30-41.
124. Fluck C, Schopflin S, Smith T, Genton B, Alpers MP, Beck HP et al. Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity. Infect Genet Evol 2007; 7:44-51.
125. Fluck C, Smith T, Beck HP, Irion A, Betuela I, Alpers MP et al. Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun 2004; 72: 6300-6305.
126. MillsKE, PearceJA, Crabb BS, Cowman AF. Truncation ofmerozoitesurfaceprotein 3 disrupts its trafficking and that of acidic-basic repeat protein to the surface of Plasmodium falciparum merozoites. Mol Microbiol 2002; 43: 1401-1411.
127. McColl DJ, Anders RF. Conservation of structural motifs and antigenic diversityin the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol 1997; 90:21-31.
128. McColl DJ, Silva A, Foley M, Kun JF, Favaloro JM, Thompson JK et al. Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol 1994; 68:53-67.
129. Escalante AA, Lal AA, Ayala FJ. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics 1998; 149: 189-202.
130. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite sur- faceprotein 3andthe220-kilodalton glutamate-rich protein. InfectImmun2004; 72: 247-252.
131. DruilheP, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2005; 2:e344.
132. Audran R, CachatM, Lurati F, SoeS, LeroyO, Corradin Get al. PhaseI malariavaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005; 73: 8017-8026.
133. OeuvrayC, Bouharoun-Tayoun H, Gras-MasseH, BottiusE, Kaidoh T, Aikawa M et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994; 84: 1594-1602.
134. Singh S, SoeS, Mejia JP, Roussilhon C, Theisen M, Corradin G et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. JInfectDis2004; 190: 1010-1018.
135. Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A et al. Safetyand immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 2007; 25: 2723-2732.
136. Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H et al. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicityand induction of biologicallyactive antibodies. Vaccine2004; 22: 1188-1198.
137. Remarque EJ, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 2008; 24:74-84.
138. Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C, Hackett F et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 2005; 308: 408-411.
139. Alexander DL, Arastu-Kapur S, Dubremetz JF, Boothroyd JC. Plasmodium falciparum AMA1 binds a rhoptry neck protein homologous to TgRON4, a component of the moving junction in Toxoplasma gondii. Eukaryot cell 2006; 5: 1169-1173.
140. Marshall VM, ZhangL, AndersRF, Coppel RL. DiversityofthevaccinecandidateAMA- 1ofPlasmodium falciparum. Mol Biochem Parasitol 1996; 77: 109-113.
141. KennedyMC, WangJ, Zhang Y, Miles AP, Chitsaz F, Saul A et al. Invitrostudies with recombinantPlasmodium falciparumapical membraneantigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 2002; 70: 6948-6960.
142. Escalante AA, Grebert HM, Chaiyaroj SC, Magris M, Biswas S, Nahlen BL et al. Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum.X.AsemboBayCohortProject. Mol Biochem Parasitol 2001; 113:279-287.
143. Cortes A, Mellombo M, Mueller I, Benet A, Reeder JC, Anders RF. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun 2003; 71: 1416-1426.
144. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, Lanar DE et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004; 23: 718-728.
145. HealerJ, MurphyV, Hodder AN, Masciantonio R, Gemmill AW, Anders RF et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody- mediated inhibition in Plasmodium falciparum. Mol Microbiol 2004; 52: 159-168.
146. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confersprotection againstblood-stagemalaria. InfectImmun2002; 70: 6961-6967.
147. Malkin EM, DiemertDJ, McArthurJH, PerreaultJR, MilesAP, GiersingBK et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005; 73: 3677-3685.
148. DickoA, DiemertDJ, SagaraI, Sogoba M, NiambeleMB, Assadou MH et al. Impactof a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS ONE 2007; 2:e1045.
149. Dicko A, Sagara I, Ellis RD, Miura K, Guindo O, Kamate B et al. Phase 1 study of a combination AMA1 blood stage malaria vaccinein Malian children. PLoSONE2008; 3:e1563.
150. Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, HayM et al. Phase1 trial of AMA1- C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 2008; 3: e2940.
151. Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adultsattheWalterReedArmyInstituteofResearch. Vaccine2007; 25: 4203-4212.
152. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA et al. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 2002; 70: 3101-3110.
153. Faber BW, Remarque EJ, Kocken CH, Cheront P, Cingolani D, Xhonneux F et al. Production, quality control, stability and pharmacotoxicity of cGMP-produced Plas- modium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris. Vaccine 2008; 26: 6143-6150.
154. Kocken CH, Withers-MartinezC, DubbeldMA, van der Wel A, HackettF, Valderrama A et al. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun 2002; 70: 4471-4476.
155. Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccineadjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoSONE2008; 3:e3960.
156. Mueller MS, Renard A, Boato F, Vogel D, Naegeli M, Zurbriggen R et al. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic ofloopI from domain III ofPlasmodiumfalciparumapical membraneantigen 1. Infect Immun 2003; 71: 4749-4758.
157. Okitsu SL, Kienzl U, Moehle K, Silvie O, Peduzzi E, Mueller MS et al. Structure- activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem Biol 2007; 14: 577-587.
158. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase 11 a clinical trial. PLoS ONE 2008; 3:e1493.
159. Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two
160. Tolia NH, Enemark EJ, Sim BK, Joshua-Tor L. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 2005; 122: 183-193.
161. Sim BK, Toyoshima T, Haynes JD, Aikawa M. Localization of the 175-kilodalton erythrocytebindingantigen in micronemesofPlasmodiumfalciparummerozoites. Mol Biochem Parasitol 1992; 51: 157-159.
162. Thompson JK, Triglia T, Reed MB, Cowman AF. A novel ligand from Plasmodium falciparum that binds to a sialic acid-containing receptor on the surface of human erythrocytes. Mol Microbiol 2001; 41:47-58.
163. Gilberger TW, Thompson JK, Triglia T, Good RT, Duraisingh MT, Cowman AF. A novel erythrocyte binding antigen-175 paralogue from Plasmodium falciparum defines a new trypsin-resistant receptor on human erythrocytes. JBiolChem2003; 278: 14480-14486.
164. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH. Receptor and ligand domains for invasion of erythrocytesbyPlasmodiumfalciparum. Science1994; 264: 1941-1944.
165. Maier AG, Duraisingh MT, Reeder JC, Patel SS, Kazura JW, Zimmerman PA et al. Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. Nature Med 2003; 9:87-92.
166. Mayer DC, Kaneko O, Hudson-Taylor DE, Reid ME, Miller LH. Characterization of a Plasmodiumfalciparumerythrocyte-bindingprotein paralogoustoEBA-175. ProcNatl AcadSci USA 2001; 98: 5222-5227.
167. Lobo CA, Rodriguez M, Reid M, Lustigman S. Glycophorin C is the receptor for the Plasmodium falciparum erythrocyte binding ligand PfEBP-2 (baebl). Blood 2003; 101: 4628-4631.
168. PandeyKC, Singh S, PattnaikP, Pillai CR, Pillai U, Lynn Aet al. Bacteriallyexpressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol Biochem Parasitol 2002; 123:23-33.
169. Narum DL, Haynes JD, Fuhrmann S, Moch K, Liang H, Hoffman SL et al. Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun 2000; 68: 1964-1966.
170. Mamillapalli A, Pattnaik P, Sharma M, Sharma SK, Tyagi PK, Joshi H et al. Sequence polymorphisms in the receptor-binding domain of Plasmodium falciparum EBA-175: implications for malaria vaccine development. Mol Biochem Parasitol 2006; 146: 120-123.
171. Okenu DM, RileyEM, BickleQD, Agomo PU, Barbosa A, DaughertyJR et al. Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect Immun 2000; 68: 5559-5566.
172. RichardsJS, StanisicDI, Wilson DW, ReilingL, KingCL, Cowman AF et al. Antibodies against the erythrocyte binding antigens and reticulocyte binding homologues of Plasmodium falciparum have a strong association with protection against clinical malaria. MAM 2008. Abstracts of the Molecular Approaches to Malaria Conference. 3-7 February 2008. Lorne, Victoria, Australia. Int J Parasitol 2008; 38(Suppl 1): S17-S98.
173. JonesTR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR, LiangH et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boostimmunization regimen. JInfectDis2001; 183: 303-312.
174. Adams JH, Hudson DE, Torii M, Ward GE, Wellems TE, Aikawa M et al. The Duffy receptor family of Plasmodium knowlesi is located within the micronemes of invasive malaria merozoites. Cell 1990; 63: 141-153.
175. Chitnis CE, Miller LH. Identification of the erythrocyte binding domains of Plasmo- dium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. JExpMed1994; 180: 497-506.
176. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. NEnglJMed1976; 295: 302-304.
177. Singh SK, Hora R, Belrhali H, Chitnis CE, Sharma A. Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. Nature 2006; 439: 741-744.
178. Grimberg BT, Udomsangpetch R, Xainli J, McHenry A, Panichakul T, Sattabongkot J et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed againstthe Duffybinding protein. PLoS Med2007; 4:e337.
179. VanBuskirk KM, Cole-Tobian JL, Baisor M, Sevova ES, Bockarie M, King CL et al. Antigenicdriftin theliganddomain ofPlasmodiumvivaxDuffybindingproteinconfers resistance to inhibitory antibodies. JInfectDis2004; 190: 1556-1562.
180. KingCL, Michon P, Shakri AR, MarcottyA, StanisicD, Zimmerman PAet al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivaxinfection. Proc Natl Acad Sci USA 2008; 105: 8363-8368.
181. Arevalo-HerreraM, CastellanosA, Yazdani SS, Shakri AR, ChitnisCE, DominikR et al. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor- binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am JTrop MedHyg2005; 73:25-31.
182. BorreMB, Dziegiel M, Hogh B, Petersen E, Rieneck K, RileyE et al. Primarystructure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol BiochemParasitol 1991; 49: 119-131.
183. Stricker K, Vuust J, Jepsen S, Oeuvray C, Theisen M. Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum. Mol Biochem Parasitol 2000; 111: 123-130.
184. Iriemenam NC, Khirelsied AH, Nasr A, Elghazali G, Giha HA, Elhassan A-Elgadir TM et al. Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine 2009; 27:62-71.
185. DodooD, AikinsA, Kusi KA, LampteyH, RemarqueE, Milligan P et al. Cohortstudyof the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. MalarJ2008; 7:142.
186. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. JInfectDis2000; 181: 1202-1205.
187. Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007; 25: 2930-2940.
188. Reiling L, Richards JS, MacCallum FJ, Persson KE, Howell K, Kinyanjui S et al. The roleofPfRh invasion ligandsastargetsofantibodiesthatprotectagainstP. falciparum malaria. MAM 2008. AbstractsoftheMolecularApproachestoMalariaConference. 37 February 2008. Lorne, Victoria, Australia. Int J Parasitol 2008; 38(Suppl 1): S17-S98.
189. Wang L, Black CG, Marshall VM, Coppel RL. Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum. Infect Immun 1999; 67: 2193-2200.
190. Polson HE, Conway DJ, Fandeur T, Mercereau-Puijalon O, Longacre S. Gene polymorphism of Plasmodium falciparum merozoite surface proteins 4 and 5. Mol Biochem Parasitol 2005; 142:110-115.
191. Wang L, Richie TL, Stowers A, Nhan DH, Coppel RL. Naturally acquired antibody responsestoPlasmodiumfalciparummerozoitesurfaceprotein 4in apopulation living in an area of endemicityin Vietnam. Infect Immun 2001; 69: 4390-4397.
192. Kedzierski L, Black CG, Coppel RL. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Infect Immun 2000; 68: 6034-6037.
193. Kedzierski L, Black CG, Goschnick MW, Stowers AW, Coppel RL. Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii. Infect Immun 2002; 70: 6606-6613.
194. Bull PC, LoweBS, KortokM, MolyneuxCS, NewboldCI, Marsh K. Parasiteantigenson the infected red cell surface are targets for naturally acquired immunity to malaria. Nature Med 1998; 4: 358-360.
195. Leech JH, Barnwell JW, Miller LH, Howard RJ. Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythro- cytes. JExpMed1984; 159: 1567-1575.
196. Biggs BA, Gooze L, WycherleyK, Wollish W, Southwell B, Leech JH et al. Antigenic variation in Plasmodium falciparum. Proc the Natl Acad Sci USA 1991; 88: 9171-9174.
197. Smith JD, Chitnis CE, Craig AG, Roberts DJ, Hudson-Taylor DE, Peterson DS et al. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 1995; 82: 101-110.
198. Bull PC, Berriman M, Kyes S, Quail MA, Hall N, Kortok MM et al. Plasmodium falciparum variant surface antigen expression patterns during Malaria. PLoS Pathog 2005; 1:e26.
199. Kaestli M, Cockburn IA, Cortes A, Baea K, RoweJA, Beck HP. Virulenceofmalaria is associated with differential expression of Plasmodium falciparum var gene subgroups in a case-control study. JInfectDis2006; 193: 1567-1574.
200. Jensen AT, Magistrado P, Sharp S, Joergensen L, Lavstsen T, Chiucchiuini A et al. Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. J Exp Med 2004; 199: 1179-1190.
201. Baruch DI, Gamain B, Barnwell JW, Sullivan JS, Stowers A, Galland GG et al. Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line. Proc Natl Acad Sci USA 2002; 99: 3860-3865.
202. Baruch DI, Gamain B, Miller LH. DNA immunization with the cysteine-rich inter- domain region 1 of the Plasmodium falciparum variant antigen elicits limited cross- reactive antibody responses. Infect Immun 2003; 71 : 4536-4543.
203. Salanti A, Dahlback M, Turner L, Nielsen MA, Barfod L, Magistrado P et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. JExpMed2004; 200: 1197-1203.
204. Trimnell AR, KraemerSM, MukherjeeS, PhippardDJ, JanesJH, FlamoeE et al. Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria. Mol BiochemParasitol 2006; 148: 169-180.
205. Beeson JG, Mann EJ, Byrne TJ, Caragounis A, Elliott SR, Brown GVet al. Antigenic differences and conservation among placental Plasmodium falciparum-infected ery- throcytes and acquisition of variant-specific and cross-reactive antibodies. JInfect Dis 2006; 193: 721-730.
206. ElliottSR, DuffyMF, ByrneTJ, Beeson JG, Mann EJ, Wilson DWet al. Cross-reactive surface epitopes on chondroitin sulfate A-adherent Plasmodium falciparum-infected erythrocytes are associated with transcription of var2csa. Infect Immun 2005; 73: 2848-2856.
207. Schofield L, Grau GE. Immunological processes in malaria pathogenesis. Nat Rev Immunol 2005; 5: 722-735.
208. Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002; 418: 785-789.
209. Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania [see comments]. Lancet1994; 344: 1175-1181.
210. AlonsoPL, Smith TA, Armstrong-SchellenbergJR, KituaAY, Masanja H, HayesR et al. Duration of protection and age-dependence of the effectsof theSPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. J Infect Dis 1996; 174: 367-372.
211. Leach A, DrakeleyCJ, D'Alessandro U, Fegan GW, BennettS, Ballou WR et al. Apilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants. Parasite Immunol 1995; 17: 441-444.
212. Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 1996; 348: 701-707.
213. Noya O, Gabaldon Berti Y, Alarcon de Noya B, Borges R, Zerpa N, Urbaez JD et al. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. JInfect Dis1994; 170:396-402.
214. Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LAet al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia [see comments]. Lancet 1993; 341: 705-710.
215. Valero MV, Amador R, Aponte JJ, Narvaez A, Galindo C, Silva Yet al. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine 1996; 14: 1466-1470.
216. Sempertegui F, Estrella B, Moscoso J, Piedrahita L, Hernandez D, Gaybor J et al. Safety, immunogenicityand protective effectof the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo- controlled field trial in an endemic area of Ecuador. Vaccine 1994; 12:337-342.
217. Amador R, Moreno A, Murillo LA, Sierra O, Saavedra D, Rojas M et al. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. JInfect Dis1992; 166: 139-144.
218. Graves P, Gelband H. Vaccines for preventing malaria (SPf66). Cochrane Database of Syst Rev 2006, CD005966.
219. Tine JA, Lanar DE, Smith DM, Wellde BT, Schultheiss P, Ware LA et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falci- parummalaria. Infect Immun 1996; 64: 3833-3844.
220. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccinecandidatefor Plasmodiumfalciparummalaria. JInfectDis1998; 177: 1664-1673.
221. Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N et al. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded byrecombinantpoxviruses. ProcNatl AcadSci USA 2004; 101: 290-295.
222. Boddey JA, Moritz RL, Simpson RJ, Cowman AF. Role of the Plasmodium export element in trafficking parasite proteins to the infected erythrocyte. Traffic 2009; 10: 285-299.
223. Maier AG, Rug M, O'Neill MT, Brown M, Chakravorty S, Szestak T et al. Exported proteinsrequiredfor virulenceand rigidityofPlasmodiumFalciparum-infected human erythrocytes. Cell 2008; 134:48-61.
224. Tonkin CJ, Kalanon M, McFadden GI. Protein targetingtothemalariaparasiteplastid. Traffic 2008; 9:166-175.
225. Yang X, Adda CG, Keizer DW, MurphyVJ, Rizkalla MM, Perugini MA et al. Apartially structured region ofa largelyunstructured protein, Plasmodiumfalciparummerozoite surface protein 2 (MSP2), forms amyloid-like fibrils. JPept Sci 2007; 13: 839-848.
226. Bai T, Becker M, Gupta A, Strike P, MurphyVJ, Anders RF et al. Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. ProcNatl AcadSciUSA2005; 102: 12736-12741.
227. ColeyAM, GuptaA, MurphyVJ, Bai T, Kim H, AndersRF et al. Structureofthemalaria antigen AMA1 in complex with a growth-inhibitory antibody. PLoS Pathog2007; 3: 1308-1319.
228. Babon JJ, Morgan WD, KellyG, Eccleston JF, FeeneyJ, Holder AA. Structural studies on Plasmodiumvivaxmerozoitesurfaceprotein-1. MolBiochemParasitol2007; 153: 31-40.
229. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA, Angov E et al. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. JMolBiol2001; 307: 1381-1394.
230. SinghS,MiuraK,ZhouH,MuratovaO,KeeganB,MilesAet al. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 2006; 74: 4573-4580.
231. Dutta S, Lee SY, Batchelor AH, Lanar DE. Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl AcadSci USA 2007; 104: 12488-12493.
232. Howell DP, Samudrala R, Smith JD. Disguising itself-insights into Plasmodium falciparumbindingand immuneevasion from theDBL crystal structure. MolBiochem Parasitol 2006; 148:1-9.
233. Tippett E, Fernandes LA, Rogerson SJ, Jaworowski A. A novel flow cytometric phagocytosis assay of malaria-infected erythrocytes. J Immunol Methods 2007; 325:42-50.
234. Persson KE, Lee CT, Marsh K, Beeson JG. Development and optimization of high- throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. JClin Microbiol 2006; 44: 1665-1673.
235. John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, King CL et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood- stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. JImmunol2004; 173: 666-672.
236. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS et al. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falci- parum. PLoS ONE 2008; 3:e3571.
237. Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibodyresponses. PLoSONE2008; 3:e2830.
238. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J et al. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoSONE2008; 3: e3557.
239. Murhandarwati EE, Black CG, Wang L, Weisman S, Koning-Ward TF, Baird JK et al. Acquisition of invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoitesurfaceprotein 1 in a transmigrantpopulation requiresmultipleinfections. JInfectDis2008; 198: 1212-1218.
240. Thompson J, Millington OR, GarsideP, Brewer JM. Whatcan transgenic parasites tell us about the development of Plasmodium-specific immune responses? Parasite Immunol 2008; 30: 223-233.
241. McIntosh RS, Shi J, JenningsRM, Chappel JC, deKoning-Ward TF, Smith Tet al. The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog 2007; 3:e72.
242. WithersMR, McKinneyD, Ogutu BR, Waitumbi JN, Milman JB, ApolloOJ et al. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials2006; 1:e32.
243. Huaman MC, Martin LB, Malkin E, Narum DL, Miller LH, Mahanty S et al. ExVivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J Immunol 2008; 180: 1451-1461.
244. Horii T. Malaria vaccine. Nippon Rinsho 2008; 66: 1990-1998